
-
Vaxcyte NasdaqGS:PCVX Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Location: 825 Industrial Road, San Carlos, CA, 94070, United States | Website: https://vaxcyte.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.647B
Cash
1.672B
Avg Qtr Burn
-114.9M
Short % of Float
11.64%
Insider Ownership
0.66%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VAX-24 Details Invasive pneumococcal disease, Infectious disease | Phase 3 Data readout | |
VAX-31 Details Infectious disease, Invasive pneumococcal disease, Vaccine | Phase 3 Initiation | |
VAX-31 Details Invasive pneumococcal disease | Phase 2 Data readout | |
VAX-24 Details Infectious disease, Invasive pneumococcal disease | Phase 2 Data readout |